Once upon a time the Self: cinema and online identity playground tales

ABSTRACT More than any other medium, Cinema can express the ‘spirit’ of modern industrial civilization (Abruzzese, 2006; 2008; Casetti, 2008), by telling about other media (Frezza, 1996; 2014) through the post-modern phase up to the present Post-Media age (Krauss, 2004) even foreshadowing the mediascape evolution (Young, 2006). Over the last decade Cinema has told about social media as complex contests where identity building or re-configuration take place. Identity’s building is an on-going and almost infinite process, well expressed by the concept of identization (Melucci, 1991). This process grounds on the reflexive project of the self (Giddens, 1992), and on individuals’ abilities to assume each other’s perspective in order to be self-reflective (Cooley, 1902; Mead, 1934; Schutz, 1962); it spreads from the internal conversation (Archer 2003) and the narrative process (Bruner, 1990; Ricoeur, 1991; Pecchinenda, 2008). Social media make these perspectives cutting-edge since they allow subjectivization practices and offer the opportunity for identity textualization (Salzano, 2008), enhancing the dialectic between the embodied self and the desired self (Salzano, 2014). For instance, Memorable moi (2013) is a short film which tells the obsession regarding the identity acknowledgment. Some scholars claim a sort of disconnection between online and offline: late modernity identity — by means of digital media — is uninhibited and non-conforming (Reid 1991), or fluid and fragmented (Turkle, 1984; 1995) — because of the disembodiment — or alone despite always connected (Turkle, 2011). This kind of disconnection is told by several cinematic storytelling (Catfish, 2010, Acht Blumen, 2012). According to other scholars, the digital Self is stable and sustained (Baym 1998), though disseminated along multiple relationships and conversations: it is rather enriched thanks to the connected reflexivity (Ito, 2008; Baym and boyd, 2012; Boccia Artieri, 2012) and anchored to the body presence — even though in a mediated form. Two movies, among others, tell about the body as an ‘identity stake’ through the digital interactions: Me, You and Everyone We Know (2005) and Her (2013). In particular, social media platforms work as identity playground during Adolescence (boyd, 2008; 2014; Buckingham, 2008): young people’s identity-in-action (Weber and Mitchell, 2008) builds up between on line and offline interactions (Hine, 2000; 2013). Many movies tell about these identity performance, ranging over the sexual identity building (InCONTACT, 2012) or the political one (The Real Social Network, 2012, #chicagoGirl: The Social Network Takes on A Dictator, 2013); others focus on the reputation management of the online identity (Chef, 2014), or on the offline augmentation of mediated relations (Face 2 Face, 2012). Cinema also describes the other side of the coin. Many movies about young people and media — which can be analyzed by means of an anthropo-mediologic approach (Frezza, 2014 ) — tell about the risks regarding the online identity building: the cyberbullying (Disconnect, 2014), the problems in the identification processes (Adoration, 2008, Chatroom, 2011), the good judgment (Hard Candy, 2005) and the mourning (UnFRIEND, 2014). Matrix (1999) is the founder of those movies which tell about the online dark side where, following Foucault (1988) the Self fluidity is intended as a consequence and expression of Power. As for this point of view, social media are interpreted as cultural device that trigger — by means of technical constraints (Couldry, 2010) and individuals’ control — a sociable power (Colombo, 2013) which imposes to conform the imagined audience and the social stereotypes. Documentaries like We Live in Public (2009), Generation Social (2012), Online Now (2012), InRealLife (2013), Terms And Conditions May Apply (2013) and the short movie Look Up (2014) describe the complaint of social media power and effect in the individuals’ daily life. Once upon a time the Self: cinema and online identity playground tales (PDF Download Available). Available from: http://www.researchgate.net/publication/280224702_Once_upon_a_time_the_Self_cinema_and_online_identity_playground_tales [accessed Nov 22, 2015]

From BEXUS to HEMERA: The application of lessons learned on the development and manufacturing of stratospheric payloads at S5Lab

In the last years the S5Lab (Sapienza Space Systems and Space Surveillance Laboratory) from Sapienza University of Rome has given to the students the opportunity to gather knowledge on stratospheric payloads by supporting the design and development of two experiments selected for the participation in the REXUS/BEXUS educational Programme, managed by three european space institutions. The insights and lessons learned gathered during the participations in the REXUS/BEXUS educational programme gave the possibility to the student to take part in the development of a third experiment in the frame of the professional research programme HEMERA and complete it successfully. STRATONAV (STRATOspheric NAVigation experiment) was a stratospheric experiment based on Software Defined Radios (SDRs) technology whose aim was the testing of the VOR (VHF Omnidirectional Range) navigation system, evaluating its performance above the standard service volume, which was launched on BEXUS 22 in October 2016. TARDIS (Tracking and Attitude Radio-based Determination In Stratosphere) was developed as a follow up of STRATONAV between 2018 and 2019. Similarly to its predecessor TARDIS was a stratospheric experiment aimed at exploiting the VOR signal, with the aid of SDRs, to perform in-flight attitude and position determination, and was launched on BEXUS 28 in October 2019. After the launch of TARDIS, a team composed both by former STRATONAV and TARDIS students was formed for the development of a third stratospheric experiment going by the name of STRAINS (Stratospheric Tracking Innovative Systems), conceived by Sapienza University of Rome and ALTEC and supported by ASI. STRAINS main objective was the proof of concept of the possibility of achieving the Time Difference of Arrival (TDOA) and the Frequency Difference of Arrival (FDOA) for navigation purposes with the aid of SDRs. The experiment was developed between 2020 and 2021 exploiting the lessons learned from the former team members of the two BEXUS campaigns and was launched on board of the Hemera H2020 stratospheric balloon in September 2021 from Esrange Space Center, Kiruna, Sweden. After a brief description of the stratospheric payloads design and manufacturing, the paper will present the major lessons learned from the previous stratospheric experiments, STRATONAV and TARDIS, and their application to the development and manufacturing of the latest launched stratospheric experiment STRAINS, as well as their educational return to the students involved in the projects

Six-month psychophysical evaluation of olfactory dysfunction in patients with COVID-19

This study prospectively assessed the six-month prevalence of self-reported and psychophysically measured olfactory dysfunction in subjects with mild-to-moderate COVID-19. Self-reported smell or taste impairment was prospectively evaluated by SNOT-22 at diagnosis, 4-week, 8-week, and 6-month. At 6 months from the diagnosis, psychophysical evaluation of olfactory function was also performed using the 34-item culturally adapted University of Pennsylvania Smell Identification Test (CA-UPSIT). 145 completed both the 6-month subjective and psychophysical olfactory evaluation. According to CA-UPSIT, 87 subjects (60.0%) exhibited some smell dysfunction, with 10 patients being anosmic (6.9%) and 7 being severely microsmic (4.8%). At the time CA-UPSIT was administered, a weak correlation was observed between the self-reported alteration of sense of smell or taste and olfactory test scores (Spearman's r=-0.26). Among 112 patients who self-reported normal sense of smell at last follow-up, CA-UPSIT revealed normal smell in 46 (41.1%), mild microsmia in 46 (41.1%), moderate microsmia in 11 (9.8%), severe microsmia in 3 (2.3%), and anosmia in 6 (5.4%) patients; however, of those patients self-reporting normal smell but who were found to have hypofunction on testing, 62 out of 66 had self-reported reduction in sense of smell or taste at an earlier time point. Despite most patients report a subjectively normal sense of smell, we observed a high percentage of persistent smell dysfunction at 6 months from the diagnosis of SARS-CoV-2 infection, with 11.7% of patients being anosmic or severely microsmic. These data highlight a significant long-term rate of smell alteration in patients with previous SARS-COV-2 infection

Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature

[Background] This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions.[Methods] Twenty sarcoma reference centres contributed data. Patients with advanced EHE diagnosed from 2000 onwards and treated with systemic therapies, were selected. Local pathologic review and molecular confirmation were required. Radiological response was retrospectively assessed by local investigators according to RECIST. Progression free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method.[Results] Overall, 73 patients were included; 21 had more than one treatment. Thirty-three patients received anthracyclines regimens, achieving 1 (3%) partial response (PR), 25 (76%) stable disease (SD), 7 (21%) progressive disease (PD). The median (m-) PFS and m-OS were 5.5 and 14.3 months respectively. Eleven patients received paclitaxel, achieving 1 (9%) PR, 6 (55%) SD, 4 (36%) PD. The m-PFS and m-OS were 2.9 and 18.6 months, respectively. Twelve patients received pazopanib, achieving 3 (25%) SD, 9 (75%) PD. The m-PFS and m-OS were.2.9 and 8.5 months, respectively. Fifteen patients received INF-α 2b, achieving 1 (7%) PR, 11 (73%) SD, 3 (20%) PD. The m-PFS and m-OS were 8.9 months and 64.3, respectively. Among 27 patients treated with other regimens, 1 PR (ifosfamide) and 9 SD (5 gemcitabine +docetaxel, 2 oral cyclophosphamide, 2 others) were reported.[Conclusion] Systemic therapies available for advanced sarcomas have limited activity in EHE. The identification of new active compounds, especially for rapidly progressive cases, is acutely needed.Peer reviewe

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152621/1/cncr32508_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/152621/2/cncr32508.pd

The pituitary tumor transforming gene 1 (PTTG-1): An immunological target for multiple myeloma

<p>Abstract</p> <p>Background</p> <p>Multiple Myeloma is a cancer of B plasma cells, which produce non-specific antibodies and proliferate uncontrolled. Due to the potential relapse and non-specificity of current treatments, immunotherapy promises to be more specific and may induce long-term immunity in patients. The pituitary tumor transforming gene 1 (PTTG-1) has been shown to be a novel oncogene, expressed in the testis, thymus, colon, lung and placenta (undetectable in most other tissues). Furthermore, it is over expressed in many tumors such as the pituitary adenoma, breast, gastrointestinal cancers, leukemia, lymphoma, and lung cancer and it seems to be associated with tumorigenesis, angiogenesis and cancer progression. The purpose was to investigate the presence/rate of expression of PTTG-1 in multiple myeloma patients.</p> <p>Methods</p> <p>We analyzed the PTTG-1 expression at the transcriptional and the protein level, by PCR, immunocytochemical methods, Dot-blot and ELISA performed on patient's sera in 19 multiple myeloma patients, 6 different multiple myeloma cell lines and in normal human tissue.</p> <p>Results</p> <p>We did not find PTTG-1 presence in the normal human tissue panel, but PTTG-1 mRNA was detectable in 12 of the 19 patients, giving evidence of a 63% rate of expression (data confirmed by ELISA). Four of the 6 investigated cell lines (66.6%) were positive for PTTG-1. Investigations of protein expression gave evidence of 26.3% cytoplasmic expression and 16% surface expression in the plasma cells of multiple myeloma patients. Protein presence was also confirmed by Dot-blot in both cell lines and patients.</p> <p>Conclusion</p> <p>We established PTTG-1's presence at both the transcriptional and protein levels. These data suggest that PTTG-1 is aberrantly expressed in multiple myeloma plasma cells, is highly immunogenic and is a suitable target for immunotherapy of multiple myeloma.</p

Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation

Background: Estrogen receptors alpha (ERa) and beta (ERb) are transcription factors (TFs) that mediate estrogen signaling and define the hormone-responsive phenotype of breast cancer (BC). The two receptors can be found co-expressed and play specific, often opposite, roles, with ERb being able to modulate the effects of ERa on gene transcription and cell proliferation. ERb is frequently lost in BC, where its presence generally correlates with a better prognosis of the disease. The identification of the genomic targets of ERb in hormone-responsive BC cells is thus a critical step to elucidate the roles of this receptor in estrogen signaling and tumor cell biology. Results: Expression of full-length ERb in hormone-responsive, ERa-positive MCF-7 cells resulted in a marked reduction in cell proliferation in response to estrogen and marked effects on the cell transcriptome. By ChIP-Seq we identified 9702 ERb and 6024 ERa binding sites in estrogen-stimulated cells, comprising sites occupied by either ERb, ERa or both ER subtypes. A search for TF binding matrices revealed that the majority of the binding sites identified comprise one or more Estrogen Response Element and the remaining show binding matrixes for other TFs known to mediate ER interaction with chromatin by tethering, including AP2, E2F and SP1. Of 921 genes differentially regulated by estrogen in ERb+ vs ERb- cells, 424 showed one or more ERb site within 10 kb. These putative primary ERb target genes control cell proliferation, death, differentiation, motility and adhesion, signal transduction and transcription, key cellular processes that might explain the biological and clinical phenotype of tumors expressing this ER subtype. ERb binding in close proximity of several miRNA genes and in the mitochondrial genome, suggests the possible involvement of this receptor in small non-coding RNA biogenesis and mitochondrial genome functions. Conclusions: Results indicate that the vast majority of the genomic targets of ERb can bind also ERa, suggesting that the overall action of ERb on the genome of hormone-responsive BC cells depends mainly on the relative concentration of both ERs in the cell

Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?

BACKGROUND: As yet, no population-based prospective studies have been conducted to investigate the incidence and clinical outcome of glioblastoma (GBM) or the diffusion and impact of the current standard therapeutic approach in newly diagnosed patients younger than aged 70 years. METHODS: Data on all new cases of primary brain tumors observed from January 1, 2009, to December 31, 2010, in adults residing within the Emilia-Romagna region were recorded in a prospective registry in the Project of Emilia Romagna on Neuro-Oncology (PERNO). Based on the data from this registry, a prospective evaluation was made of the treatment efficacy and outcome in GBM patients. RESULTS: Two hundred sixty-seven GBM patients (median age, 64 y; range, 29-84 y) were enrolled. The median overall survival (OS) was 10.7 months (95% CI, 9.2-12.4). The 139 patients 64aged 70 years who were given standard temozolomide treatment concomitant with and adjuvant to radiotherapy had a median OS of 16.4 months (95% CI, 14.0-18.5). With multivariate analysis, OS correlated significantly with KPS (HR = 0.458; 95% CI, 0.248-0.847; P = .0127), MGMT methylation status (HR = 0.612; 95% CI, 0.388-0.966; P = .0350), and treatment received in a high versus low-volume center (HR = 0.56; 95% CI, 0.328-0.986; P = .0446). CONCLUSIONS: The median OS following standard temozolomide treatment concurrent with and adjuvant to radiotherapy given to (72.8% of) patients aged 6470 years is consistent with findings reported from randomized phase III trials. The volume and expertise of the treatment center should be further investigated as a prognostic factor

Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study

Background: The National Research Council (CNR) prostate cancer monitoring project in Italy (Pros-IT CNR) is an observational, prospective, ongoing, multicentre study aiming to monitor a sample of Italian males diagnosed as new cases of prostate cancer. The present study aims to present data on the quality of life at time prostate cancer is diagnosed. Methods: One thousand seven hundred five patients were enrolled. Quality of life is evaluated at the time cancer was diagnosed and at subsequent assessments via the Italian version of the University of California Los Angeles-Prostate Cancer Index (UCLA-PCI) and the Short Form Health Survey (SF-12). Results: At diagnosis, lower scores on the physical component of the SF-12 were associated to older ages, obesity and the presence of 3+ moderate/severe comorbidities. Lower scores on the mental component were associated to younger ages, the presence of 3+ moderate/severe comorbidities and a T-score higher than one. Urinary and bowel functions according to UCLA-PCI were generally good. Almost 5% of the sample reported using at least one safety pad daily to control urinary loss; less than 3% reported moderate/severe problems attributable to bowel functions, and sexual function was a moderate/severe problem for 26.7%. Diabetes, 3+ moderate/severe comorbidities, T2 or T3-T4 categories and a Gleason score of eight or more were significantly associated with lower sexual function scores at diagnosis. Conclusions: Data collected by the Pros-IT CNR study have clarified the baseline status of newly diagnosed prostate cancer patients. A comprehensive assessment of quality of life will allow to objectively evaluate outcomes of different profile of care